Skip to content
Screener

Boston Scientific BSX Payment to net share settle employee equity awards

Payment to net share settle employee equity awards at other companies

Warner Bros. Discovery, Inc. logo
Warner Bros. Discovery, Inc.WBD
$29M
AlTi Global, Inc. logo
AlTi Global, Inc.ALTI
$8.11M+10.5%
Royalty Pharma logo
Royalty PharmaRPRX
$4.55M+2,529%
Royalty Pharma logo
Royalty PharmaRPRX
$4.55M+2,529%
GoodRx Holdings, Inc. logo
GoodRx Holdings, Inc.GDRX
$3.19M-29.9%
GoodRx Holdings, Inc. logo
GoodRx Holdings, Inc.GDRX
$3.19M-29.9%

Other financials

Income statement

See full
Revenue$5.4B+7.5%
Gross profit$3.8B+12.4%
Operating income$1.2B+43.8%
Net income$907.0M+14.1%
EPS (diluted)$0.61+15.1%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total debt$659.0M-94.1%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.3%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$71.45B-53.2%
P/E19.5×-41.6×
P/S3.4×-4.8×

Profitability

See full
Gross margin69.9%+1.7pp
Operating margin19.8%+2.8pp
Net margin17.5%+4.0pp
FCF margin16.9%-0.3pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept bsx:Paymenttonetsharesettleemployeeequityawards.

The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 6:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000885725-26-000033
(in millions)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Payments on short-term borrowings(259)(1,083)
Net increase (decrease) in commercial paper(192)
Proceeds from long-term borrowings, net of debt issuance costs1,558
Cash used to net share settle employee equity awards(85)(118)
Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans81115
Other, net3(10)
Cash provided by (used for) financing activities(260)233
Effect of foreign exchange rates on cash(0)39

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Boston Scientific's payment to net share settle employee equity awards?
Boston Scientific (BSX) reported payment to net share settle employee equity awards of $85M in Q1 2026.
How has Boston Scientific's payment to net share settle employee equity awards changed year-over-year?
Boston Scientific's payment to net share settle employee equity awards decreased by 28.0% year-over-year, from $118M to $85M.
What is the long-term trend for Boston Scientific's payment to net share settle employee equity awards?
Over 4 years (2021 to 2025), Boston Scientific's payment to net share settle employee equity awards has grown at a 27.2% compound annual growth rate (CAGR), from $50M to $131M.
What does payment to net share settle employee equity awards mean?
Cash paid by the company to satisfy tax withholding obligations when employees exercise equity awards, where the company withholds a portion of the shares to cover the tax liability. This is a non-dilutive way to manage equity compensation.

Ask your AI about Boston Scientific's payment to net share settle employee equity awards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude